Cyclo Therapeutics Inc. - CYTH Net earnings per one share for the last twelve months

Cyclo Therapeutics generates revenue by developing cyclodextrin-based drugs for specialized centers and patients with Alzheimer's disease. The company raises capital from investors to cover the costs of final clinical trials. Price action depends on the success of Trappsol Cyclo in treating Niemann-Pick disease. This rolling year-over-year EPS chart visualizes earnings, where the -5.40 metric determines this level.
Cyclo Therapeutics - analytical breakdowns and key metrics (CYTH)

Cyclo Therapeutics (CYTH) is integrating ESG standards into the synthesis of cyclodextrin-based drugs to minimize laboratory waste. The percentage change in earnings per share over the last four quarters defines the calculation logic of this ratio. This metric allows for an assessment of capital management efficiency and the actual speed of business scaling. It is critical for investors to compare these rates with industry benchmarks to avoid overpaying for the asset. An analysis of net income per share growth YoY ttm clearly reveals deviations from the market trend.